Coronavirus
The FDA and Johnson & Johnson Are Expected to Announce That the Issues at Emergent BioSolutions Have Been Resolved
The Food and Drug Administration and Johnson & Johnson expect to announce that COVID-19 vaccine contamination problems at a facility in Baltimore have been resolved, The Wall Street Journal reported.
U.S. officials told the newspaper that emergency use authorization for the Emergent BioSolutions facility to produce J&J’s vaccine could come next week.
One official told the newspaper Emergent’s plant has produced millions of doses but most aren’t finished and are placed in vials, meaning it could take months before all the doses are ready.
